| ||||||
| 8229 Boone Boulevard, Suite 802, Vienna, VA, 22182, US. TEL: 703-506-9460 http://www.cel-sci.com | ||||||
| Last Sale | Net Change | % Change | Volume | Last Updated | ||
|---|---|---|---|---|---|---|
| $1.30 | 0.01 | 0.78 | 3,231,176 | 11/20/09 4:02 PM ET | ||
| ||||||||||||||||||||||
 |
|
||||||||||||||||||||||
| ||||
| Security Type | Common Stock | Specialist | 076 | |
| Industry | Health Services, Pharmaceuticals, and Medical Diagnostics | Trading Post | 2 | |
| Primary Exchange | NYSE Amex | SEC Filings | ||
| ||||
| Description |
|
CEL-SCI Corporation engages in the research and development of drugs and vaccines used in the treatment of cancer. The company's lead product includes Multikine, which is under development for the treatment of cancer and is cleared for a Phase III clinical trial in advanced primary head and neck cancer patients. Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines, including interleukins, interferons, chemokines, and colony-stimulating factors. The company also develops CEL-1000, which is derived from a pre-clinical technology called `Ligand Epitope Antigen Presentation System' for protection for animals against avian flu, herpes, malaria, viral encephalitis, smallpox, vaccinia, and cancer, as well as CEL-2000, for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is based in Vienna, Virginia. |
| Quote |
| ||||
| Last Sale | $1.30 (11/20/09) | |||
| Net Change | 0.01 | |||
| % Change | 0.78 | |||
| Previous Close | $1.29 | |||
| Today’s Open | $1.28 | |||
| Today’s High | $1.35 | |||
| Today’s Low | $1.25 | |||
| Volume | 3,231,176 | |||
| 52 Week High | $2.10 | |||
| 52 Week Low | $0.14 | |||
| ||||
| Chart |
| 3mo | 6mo | 12mo | 24mo | 36mo | 48mo | 60mo |
|
| Click here to view the data behind the chart. |
| Fundamentals |
|
||||
| P/E ratio | -14.33 | Short Interest | 10,425,778 | |
| Earnings Per Share | -0.09 | Current yield | N.A. | |
| Shares Outstanding | 162,984,000 | Dividend Info | ||
| Market Cap | 211,879,200 | |||
|
||||
|
|
